<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Metab Syndr Obes</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Metab Syndr Obes</journal-id><journal-id journal-id-type="publisher-id">DMSO</journal-id><journal-id journal-id-type="pmc">dmso</journal-id><journal-title-group><journal-title>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</journal-title></journal-title-group><issn pub-type="epub">1178-7007</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32021349</article-id><article-id pub-id-type="pmc">6954851</article-id><article-id pub-id-type="publisher-id">220046</article-id><article-id pub-id-type="doi">10.2147/DMSO.S220046</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Evaluation of the Effect of Fish Oil Alone and in Combination with a Proprietary Chromium Complex on Endothelial Dysfunction, Systemic Inflammation and Lipid Profile in Type 2 Diabetes Mellitus &#x02013; A Randomized, Double-Blind, Placebo-Controlled Clinical Study</article-title><alt-title alt-title-type="running-authors">Pingali et al</alt-title><alt-title alt-title-type="running-title">Pingali et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pingali</surname><given-names>Usharani</given-names></name><xref ref-type="corresp" rid="AN0001"/><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0529-2706</contrib-id><name><surname>Nutalapati</surname><given-names>Chandrasekhar</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Illendulla</surname><given-names>Vijay Sravanthi</given-names></name><xref ref-type="aff" rid="AFF0002">2</xref></contrib><aff id="AFF0001"><label>1</label><institution>Department of Clinical Pharmacology &#x00026; Therapeutics, Nizam&#x02019;s Institute of Medical Sciences</institution>, <addr-line>Hyderabad</addr-line>, <addr-line>Telangana</addr-line>, <addr-line>500082</addr-line>, <country>India</country></aff><aff id="AFF0002"><label>2</label><institution>Govt. Ayurvedic Dispensary, Primary Health Center Gummadidala,</institution>
<addr-line>Sangareddy</addr-line>, <addr-line>Telangana</addr-line>, <addr-line>502313</addr-line>, <country>India</country></aff></contrib-group><author-notes><corresp id="AN0001">Correspondence: Usharani Pingali <institution>Department of Clinical Pharmacology &#x00026; Therapeutics, Nizam&#x02019;s Institute of Medical Sciences</institution>, <addr-line>Hyderabad</addr-line><addr-line>500082</addr-line>, <addr-line>Telangana</addr-line>, <country>India</country><phone>Tel +91 9849574143</phone> Email ushapingali@yahoo.com</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>13</volume><fpage>31</fpage><lpage>42</lpage><history><date date-type="received"><day>19</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>07</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Pingali et al.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Pingali et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><sec id="S2001"><title>Purpose</title><p>This study was conducted to evaluate the effectiveness of fish oil alone and with an adjunct, a proprietary chromium complex (PCC), on cardiovascular parameters &#x02013; endothelial dysfunction, lipid profile, systemic inflammation and glycosylated hemoglobin &#x02013; in a 12-week randomized, double-blind, placebo-controlled clinical study in type 2 diabetes mellitus subjects.</p></sec><sec id="S2002"><title>Patients and Methods</title><p>In this randomized, double-blind, parallel group study, 59 subjects in three groups completed the study: Group A, fish oil 2000 mg; Group B, fish oil 2000 mg + PCC 10 mg (200 &#x000b5;g of Cr<sup>3+</sup>); and Group C, fish oil 2000 mg + PCC 20 mg (400 &#x000b5;g of Cr<sup>3+</sup>) daily for 12 weeks (2000 mg of fish oil contained 600 mg of eicosapentaenoic acid [EPA] and 400 mg of docosahexaenoic acid [DHA], the omega-3 fatty acids). Endothelial function, by estimating reflection index (RI), biomarkers of oxidative stress (nitric oxide [NO], malondialdehyde [MDA], glutathione [GSH]) and inflammatory biomarkers (high-sensitivity C-reactive protein [hsCRP], intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1], endothelin-1) were evaluated at baseline, and 4 and 12 weeks. Lipid profile, platelet aggregation and glycosylated hemoglobin [HbA1c) were tested at baseline and 12 weeks. Any reported adverse drug reactions &#x0feff;were recorded. Statistical analysis was performed using GraphPad Prism 8.</p></sec><sec id="S2003"><title>Results</title><p>The present study shows that fish oil by itself, at a dose of 2000 mg (600 mg of EPA + 400 mg of DHA) per day, led to significant, but only modest, improvement in cardiovascular parameters (&#x0feff;RI from &#x02212;2.38&#x000b1;0.75 to &#x02212;3.92&#x000b1;0.60, MDA from 3.77&#x000b1;0.16 to 3.74&#x000b1;0.16 nM/mL, NO from 30.60&#x000b1;3.18 to 32.12&#x000b1;3.40 &#x000b5;M/L, GSH from 568.93&#x000b1;5.91 to 583.95&#x000b1;6.53 &#x000b5;M/L; p&#x02264;0.0001), including triglyceride levels. However, when PCC was added to fish oil, especially at the 20 mg dose, there were highly significant improvements in all the parameters tested &#x0feff;(RI from &#x02212;2.04&#x000b1;0.79 to &#x02212;8.73&#x000b1;1.36, MDA from 3.67&#x000b1;0.39 to 2.89&#x000b1;0.34 nM/mL, NO from 28.98&#x000b1;2.93 to 40.01&#x000b1;2.53 &#x000b5;M/L, GSH from 553.82&#x000b1;8.18 to 677.99&#x000b1;10.19 &#x000b5;M/L; p&#x02264;0.0001), including the lipid profile. It is noteworthy that the triglycerides were decreased significantly by addition of 20 mg of PCC although the dose of fish oil was only 2 g/day and the baseline triglyceride levels were only about 200 mg/dL. Fish oil alone did not significantly decrease the HbA1c, whereas the addition of 20 mg of PCC did.</p></sec><sec id="S2004"><title>Conclusion</title><p>Addition of PCC, especially at 20 mg dose, significantly improves the efficacy of fish oil in addressing cardiovascular risk factors compared to fish oil given alone.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>fish oil</kwd><kwd>Crominex<sup>&#x000ae;</sup></kwd><kwd>diabetes mellitus</kwd><kwd>omega-3 fatty acids</kwd><kwd>trivalent chromium</kwd><kwd>Cr3+</kwd></kwd-group><counts><fig-count count="1"/><table-count count="5"/><ref-count count="71"/><page-count count="12"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>Cardiovascular diseases (CVDs), which include coronary heart disease (CHD) and cerebrovascular diseases, account for 21.9% of total mortality and are predicted to increase to 26.3% by 2030. They are said to be the dominant cause of death globally.</p><p>CVD is a major cause of death and disability among people with type 2 diabetes mellitus (T2DM). Adults with diabetes historically have a higher prevalence rate of CVD than adults without diabetes, and the risk of CVD increases continuously with rising fasting plasma glucose levels, even before reaching levels sufficient for a diabetes diagnosis. Among the specific diseases within that term, coronary artery disease is supposed to be the most lethal. An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Of these deaths, 85% are due to heart attack and stroke.<xref rid="CIT0001" ref-type="bibr">1</xref><sup>&#x02013;</sup><xref rid="CIT0003" ref-type="bibr">3</xref></p><p>Endothelial dysfunction (EnD) is presumed to play a significant role in the development of microvascular and macrovascular disease, causing a considerable increase in atherosclerotic vascular disease.<xref rid="CIT0003" ref-type="bibr">3</xref> Diminished bioavailability of the vasodilator nitric oxide (NO), chiefly due to increase in the deterioration of NO levels by reactive oxygen species (ROS), results in EnD.<xref rid="CIT0004" ref-type="bibr">4</xref> Oxidative stress, through a single unifying mechanism of superoxide production, is the common pathogenic factor leading to insulin resistance, &#x003b2;-cell dysfunction, impaired glucose tolerance and ultimately to T2DM. It is suspected to be the underlying cause of both the macrovascular and microvascular complications associated with T2DM. So, therapies aimed at decreasing oxidative stress would be of use in patients with T2DM, and those at risk for developing diabetes.<xref rid="CIT0005" ref-type="bibr">5</xref> T2DM is managed with oral anti-diabetic drugs. However, lifestyle modifications, such as daily exercise and diet control, are essential components in addressing the problem.</p><p>Dyslipidemia is a common feature of diabetes.<xref rid="CIT0006" ref-type="bibr">6</xref> It seems that dyslipidemia substantially alters endothelial function, causing a decrease in relaxation of the arterial vessels.<xref rid="CIT0007" ref-type="bibr">7</xref>,<xref rid="CIT0008" ref-type="bibr">8</xref> This irregularity has been observed mainly in atherosclerotic patients as well as in asymptomatic subjects with hypercholesterolemia.<xref rid="CIT0009" ref-type="bibr">9</xref>,<xref rid="CIT0010" ref-type="bibr">10</xref></p><p>Diabetes mellitus and hypertension are frequently present together. Among many microvascular complications of diabetes, hypertension has a predominant role in the progression of diabetic nephropathy by glomerular hyperfiltration. Hypertension also induces atherosclerosis in diabetes.<xref rid="CIT0011" ref-type="bibr">11</xref> Data from the MRFIT study<xref rid="CIT0012" ref-type="bibr">12</xref> show that the association between cholesterol and coronary artery disease is strong and graded across all levels of blood pressure; similarly, the association between blood pressure and coronary artery disease is strong and graded across all levels of cholesterol.</p><p>Dietary supplementation with omega-3 fatty acids (&#x003c9;-3FAs) from fish and krill oils has been a popular way to improve the lipid profile, especially the triglyceride (TG) levels, in the blood.<xref rid="CIT0013" ref-type="bibr">13</xref>&#x02013;<xref rid="CIT0022" ref-type="bibr">22</xref> Despite the controversy regarding the benefits of &#x003c9;-3FAs, as per the latest Science Advisory from the American Heart Association, treatment with &#x003c9;-3FA supplements in patients with CHD, such as myocardial infarction, is considered reasonable, and &#x003c9;-3FA treatment is also suggested for patients with prevalent heart failure without conserved left ventricular function to reduce mortality and hospitalizations.<xref rid="CIT0023" ref-type="bibr">23</xref></p><p>Proprietary chromium complex (PCC; Crominex<sup>&#x000ae;</sup> 3+) is prepared by complexation of trivalent chromium chloride with an aqueous extract of <italic>Phyllanthus emblica</italic> fruit, which contains polyphenolic compounds, and purified Shilajit, which, by virtue of its liposomal fulvic acid content, increases the bioavailability of chromium. Microcrystalline cellulose is used as a placebo carrier in the complex.<xref rid="CIT0024" ref-type="bibr">24</xref> Trivalent chromium is an essential mineral that appears to play a favorable role in the regulation of insulin action, metabolic syndrome and CVD.<xref rid="CIT0025" ref-type="bibr">25</xref>,<xref rid="CIT0026" ref-type="bibr">26</xref>
<italic>Phyllanthus emblica</italic>, generally recognized as Indian gooseberry or &#x0201c;Amla&#x0201d;, has been utilized as a well-being product for centuries in India and other Asian nations. Clinical studies in humans have proven the hypolipidemic, antioxidant and cardioprotective activities of <italic>P. emblica</italic>.<xref rid="CIT0027" ref-type="bibr">27</xref>&#x02013;<xref rid="CIT0033" ref-type="bibr">33</xref> Shilajit, a rock exudate containing free and chromoprotein-conjugated dibenzo-&#x003b1;-pyrones (urolithins) and fulvic acids as bioactives, finds broad use in Ayurveda for different clinical applications, such as improving cardiovascular health, upregulating collagen and related extracellular matrix protein genes<xref rid="CIT0034" ref-type="bibr">34</xref>&#x02013;<xref rid="CIT0038" ref-type="bibr">38</xref> Shilajit seems to induce the growth of blood vessels<xref rid="CIT0039" ref-type="bibr">39</xref> and has a prominent cardioprotective effect.<xref rid="CIT0040" ref-type="bibr">40</xref></p><p>A clinical study with &#x003c9;-3FA, in combination with another product, to broaden the spectrum of cardiovascular benefits of &#x003c9;-3FA in T2DM, without increasing the size or cost of the dosage form significantly, is warranted. PCC, which has been shown previously in T2DM patients to improve endothelial function and the lipid profile,<xref rid="CIT0041" ref-type="bibr">41</xref>&#x02013;<xref rid="CIT0043" ref-type="bibr">43</xref> may prove to be an ideal candidate to be added to &#x003c9;-3FA, as the dose is small (10&#x02013;20 mg). So, this study was planned to evaluate the effect of fish oil alone and in combination with a PCC on endothelial dysfunction, systemic inflammation and the lipid profile in T2DM subjects.</p></sec><sec id="S0002"><title>Materials and Methods</title><p>This prospective, randomized, double-blind, parallel-group study was conducted in the Department of Clinical Pharmacology and Therapeutics, Nizam&#x02019;s Institute of Medical Sciences, Hyderabad, India. The study was initiated after prior approval from the Institutional Ethics Committee. This trial was conducted in accordance with the Declaration of Helsinki. The CONSORT flow diagram is depicted in <xref rid="F0001" ref-type="fig">Figure 1</xref>. Written informed consent was obtained from all subjects prior to their participation in the study.<fig id="F0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>CONSORT flow diagram.</p></caption><graphic content-type="print-only" xlink:href="DMSO-13-31-g0001"/></fig></p><sec id="S0002-S2001"><title>Subjects</title><sec id="S0002-S2001-S3001"><title>Inclusion Criteria</title><p>The study included male and female subjects aged 30&#x02013;65 years, willing to give informed consent and to adhere to protocol-related study procedures, with fasting plasma glucose of 110&#x02013;126 mg/dL and glycosylated hemoglobin (HbA1c) between 6.5% and 8%; patients on a steady dose of anti-diabetic treatment (metformin 1500&#x02013;2500 mg/day) for the past 8 weeks preceding the screening; and with EnD (salbutamol challenge test), reported as &#x02264;6% change in reflection index (RI), and not on any investigational products in the previous 6 months.</p></sec><sec id="S0002-S2001-S3002"><title>Exclusion Criteria</title><p>Subjects were excluded if they had abnormal hematological or biochemical parameters considered significant by the investigators, uncontrolled hypertension (SBP &#x0003e;180 mmHg and DBP &#x0003e;100 mmHg), aspartate transaminase (AST) and alanine transaminase (ALT) elevation greater than three times the upper limit of normal, serum creatinine &#x0003e;1.5 mg/dL, serum triglycerides (TGs) &#x0003e;500 mg/dL, were on any other dietary or herbal supplements, and/or had any medical condition where the physician felt that participation in the study could be detrimental to their well-being.</p></sec></sec><sec id="S0002-S2002"><title>Outcome Measures</title><sec id="S0002-S2002-S3001"><title>Primary</title><p>Primary outcome measures were:
<list list-type="order"><list-item><p>Improvement in endothelial function as estimated by &#x0003e;6% change in RI and endothelial function biomarkers (nitric oxide [NO], glutathione [GSH] and malondialdehyde [MDA]), at 12 weeks in all treatment groups.</p></list-item><list-item><p>Improvement in vascular inflammation biomarkers (intercellular adhesion molecule-1 [ICAM-1], human vascular cell adhesion molecule-1 [VCAM-1] and endothelin-1 [ET-1]), systemic inflammation biomarker (high-sensitivity C-reactive protein [hsCRP]), glycosylated hemoglobin (HbA1c), platelet aggregation and lipid profile.</p></list-item></list></p></sec><sec id="S0002-S2002-S3002"><title>Secondary</title><p>The secondary outcome measure was to assess the safety and tolerability of the test medications.</p></sec></sec><sec id="S0002-S2003"><title>Randomization and Blinding</title><p>Out of 77 subjects who were screened, 62 subjects complying with the inclusion criteria were randomized by computer-generated block randomization to one of the three treatment groups in a double-blinded fashion. Three subjects dropped out of the study before the first follow-up; 59 subjects completed 12 weeks of treatment.</p><p>All the study medications (capsules) were similar in size, color, shape and texture. Each subject was given a sealed packet containing two sealed bottles, each bottle containing 33 capsules. They were instructed to take one capsule from each bottle daily each morning with water, after breakfast, for a period of 4 weeks. Thereafter, at each visit the subject was given a new sealed packet containing two sealed bottles and asked to consume the contents in the same pattern as instructed earlier.<list list-type="bullet"><list-item><p>Group A: one capsule from each bottle once a day, each soft gelatin capsule containing 1000 mg of a refined fish oil concentrate having 300 mg of eicosapentaenoic acid (EPA) (TG) and 200 mg of docosahexaenoic acid (DHA) (TG), to provide a total dose of 2000 mg of fish oil concentrate per day.</p></list-item></list><list list-type="bullet"><list-item><p>Group B: one capsule from each bottle once a day, one bottle containing a soft gelatin capsule of 1000 mg of a refined fish oil concentrate having 300 mg of EPA (TG) and 200 mg of DHA (TG), and the other bottle containing a soft gelatin capsule of 1000 mg of a refined fish oil concentrate, containing 300 mg of EPA (TG) and 200 mg of DHA (TG), and 10 mg of PCC (equivalent to 200 &#x000b5;g of trivalent chromium) to provide a total dose of 2000 mg of fish oil and 10 mg of PCC (equivalent to 200 &#x000b5;g of trivalent chromium) per day.</p></list-item></list><list list-type="bullet"><list-item><p>Group C: one capsule from each bottle once a day, each soft gelatin capsule containing 1000 mg of a refined fish oil concentrate having 300 mg of EPA (TG) and 200 mg of DHA (TG), and 10 mg of PCC (equivalent to 200 &#x000b5;g of trivalent chromium) to provide a total dose of 2000 mg of fish oil and 20 mg of PCC (equivalent to 400 &#x000b5;g of trivalent chromium) per day.</p></list-item></list></p><p>The bottles containing the test products were sequentially designated numbers and were dispensed by the pharmacist to the subjects as per the randomly allocated sequence. The principal investigator and the subjects were blinded. After the completion of the study period the allocations were unblinded to tabulate the data and perform the statistical analyses.</p><p>All subjects were on a steady dose of concomitant medication (metformin 1500&#x02013;2500 mg/day) over previous 8 weeks as prescribed by the physician, and the same was continued throughout the study.</p></sec><sec id="S0002-S2004"><title>Follow-Up Visits</title><p>Subjects were recalled for follow-up visits at 4, 8 and 12 weeks of therapy; they were evaluated for efficacy and safety at these visits. Endothelial function as estimated by RI was performed at every visit (baseline, 4, 8 and 12 weeks). Blood samples were collected for evaluation of oxidative markers (MDA, NO, GSH) and inflammatory markers (hsCRP, ICAM-1, VCAM-1, ET-1) at baseline and 4 and 12weeks. Lipid profile, HbA1c and platelet aggregation were evaluated at baseline and at the end of 12 weeks. A complete physical examination and laboratory investigations for safety parameters including hematological, hepatic and renal biochemical parameters were conducted at baseline and at the end of 12 weeks, and, if deemed necessary, during the study. At each visit subjects were asked to report the presence of adverse drug reaction, and these were recorded in the case report form, if any. The pill-count method was adapted to check compliance with study medications. Compliance was considered good if &#x0003e;80% of the time &#x0003e;80% of medication was taken, fair if it was between 60% and 80%, and poor if it was &#x0003c;60%. In the present study the average compliance in all three groups was 90%.</p></sec><sec id="S0002-S2005"><title>Methods of Assessment</title><p>Endothelial function was evaluated by a salbutamol challenge test using digital volume plethysmography, as reported by Chowienczyk et al<xref rid="CIT0044" ref-type="bibr">44</xref> and Naidu et al.<xref rid="CIT0045" ref-type="bibr">45</xref> Subjects were examined in the supine position after 5 min of rest. A digital volume pulse (DVP) was obtained using a photoplethysmograph (Pulse Trace PCA2, PT200; Micro Medical, Kent, UK) transmitting infrared light at 940 nm, placed on the index finger of the right hand. The signal from the plethysmograph was digitized using a 12-bit analogue-to-digital converter with a sampling frequency of 100 Hz. DVP waveforms were recorded over a 20-s period and the height of the late systolic/early diastolic portion of the DVP was expressed as a percentage of the amplitude of the DVP to yield the RI, as per the procedure described in detail by Millasseau et al.<xref rid="CIT0046" ref-type="bibr">46</xref> After DVP recordings had been taken, three measurements of RI were calculated and the mean value was determined. Subjects were then administered 400 &#x000b5;g of salbutamol by inhalation. After 15 min, three measurements of RI were obtained again and the difference in mean RI before and after administration of salbutamol was used for assessing endothelial function. A decrease of &#x02264;6% in RI post-salbutamol was considered as EnD.</p><p>NO<xref rid="CIT0047" ref-type="bibr">47</xref> (by colorimetric detection with Griess reagents), MDA<xref rid="CIT0048" ref-type="bibr">48</xref> (by thiobarbituric acid reactive substance test) and GSH<xref rid="CIT0049" ref-type="bibr">49</xref> (by Ellman&#x02019;s method) levels were estimated spectrophotometrically. The ELISA method was employed to assess hsCRP, ET-1, ICAM-1 and VCAM-1 levels. Subjects were asked to come to the department after an overnight fast, for collection of samples for determination of hemoglobin, blood urea and serum creatinine, liver function tests, and lipid profile, ie, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C) and TGs, using appropriate standard techniques. A platelet aggregation test with 10 &#x000b5;M/mL ADP and 2 &#x000b5;g/mL collagen was performed by employing a platelet aggregometry test (Chrono-log light transmittance aggregometry).</p></sec><sec id="S0002-S2006"><title>Statistical Analysis</title><p>A total sample size of 78 was predicted, to enroll 66 subjects, assuming a pooled standard deviation of 2 units to achieve a power of 80%, 5% significance, screening failure of 10% and dropout rate of 10%. Study data are shown as mean &#x000b1; SD. The paired <italic>t</italic>-test was applied to compare the mean change from baseline to post-treatment (4, 8 and 12 weeks of treatment) within groups and ANOVA for between-group comparisons. Post-hoc analysis between the groups was conducted using Tukey&#x02019;s test. A p-value of &#x02264;0.05 was taken to be statistically significant. GraphPad Prism 8 software was used to conduct statistical analyses.</p></sec></sec><sec id="S0003"><title>Results</title><p>In this randomized study 59 subjects completed 12 weeks of treatment. A total of 19 subjects in Group A (fish oil 2000 mg), 20 subjects in Group B (fish oil 2000 mg + PCC 10 mg, equivalent to 200 &#x000b5;g of Cr<sup>3+</sup>) and 20 subjects in Group C (fish oil 2000 mg + PCC 20 mg, equivalent to 400 &#x000b5;g of Cr<sup>3+</sup>) completed the 12 weeks of treatment.</p><p><xref rid="T0001" ref-type="table">Table 1</xref> depicts the demographic data of the study population.<table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics of Subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameter</th><th rowspan="1" colspan="1">Fish Oil 2000 mg (Group A) (n=19)</th><th rowspan="1" colspan="1">Fish Oil 2000 mg + PCC 10 mg (Group B) (n=20)</th><th rowspan="1" colspan="1">Fish Oil 2000 mg + PCC 20 mg (Group C) (n=20)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">51.26&#x000b1;5.55</td><td rowspan="1" colspan="1">51.20&#x000b1;6.32</td><td rowspan="1" colspan="1">50.45&#x000b1;8.06</td></tr><tr><td rowspan="1" colspan="1">Gender (M/F)</td><td rowspan="1" colspan="1">10/9</td><td rowspan="1" colspan="1">10/10</td><td rowspan="1" colspan="1">12/8</td></tr><tr><td rowspan="1" colspan="1">Body weight (kg)</td><td rowspan="1" colspan="1">68.87&#x000b1;6.01</td><td rowspan="1" colspan="1">72.73&#x000b1;6.77</td><td rowspan="1" colspan="1">70.31&#x000b1;6.39</td></tr><tr><td rowspan="1" colspan="1">Height (cm)</td><td rowspan="1" colspan="1">162.2&#x000b1;7.03</td><td rowspan="1" colspan="1">161.1&#x000b1;6.43</td><td rowspan="1" colspan="1">164.9&#x000b1;5.85</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">26.28&#x000b1;1.83</td><td rowspan="1" colspan="1">28.15&#x000b1;3.04</td><td rowspan="1" colspan="1">25.62&#x000b1;1.93</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold> Values are expressed as mean &#x000b1; SD.</p></fn><fn><p><bold>Abbreviations:</bold> SD, standard deviation; BMI, body mass index.</p></fn></table-wrap-foot></table-wrap>
</p><p>As seen from <xref rid="T0002" ref-type="table">Table 2</xref>, all groups showed significant improvement in RI, illustrating an improvement in endothelial function at 12 (p&#x02264;0.0001), 8 (p&#x02264;0.0001) and 4 (p&#x02264;0.001) weeks. On further analysis, treatment in Group C gave significantly better results than in Groups B and Group A at 12 weeks (p&#x02264;0.0001).<table-wrap id="T0002" orientation="landscape" position="float"><label>Table 2</label><caption><p>Effect of Treatment on Reflection Index % (RI, Measure of Endothelial Function)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameter</th><th colspan="4" rowspan="1">Fish Oil 2000 mg (Group A) (n=19)</th><th colspan="4" rowspan="1">Fish Oil 2000 mg + PCC 10 mg (Group B) (n=20)</th><th colspan="4" rowspan="1">Fish Oil 2000 mg + PCC 20 mg (Group C) (n=20)</th></tr><tr><th rowspan="1" colspan="1">RI (%)</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">4 Weeks</th><th rowspan="1" colspan="1">8 Weeks</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">4 Weeks</th><th rowspan="1" colspan="1">8 Weeks</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">4 Weeks</th><th rowspan="1" colspan="1">8 Weeks</th><th rowspan="1" colspan="1">12 Weeks</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mean &#x000b1; SD</td><td rowspan="1" colspan="1">&#x02212;2.38&#x000b1;0.75</td><td rowspan="1" colspan="1">&#x02212;2.73&#x000b1;0.73</td><td rowspan="1" colspan="1">&#x02212;3.42&#x000b1;0.71</td><td rowspan="1" colspan="1">&#x02212;3.92&#x000b1;0.60</td><td rowspan="1" colspan="1">&#x02212;1.78&#x000b1;0.70</td><td rowspan="1" colspan="1">&#x02212;2.50&#x000b1;0.68</td><td rowspan="1" colspan="1">&#x02212;3.76&#x000b1;0.72</td><td rowspan="1" colspan="1">&#x02212;4.88&#x000b1;0.80</td><td rowspan="1" colspan="1">&#x02212;2.04&#x000b1;0.79</td><td rowspan="1" colspan="1">&#x02212;3.48&#x000b1;0.83</td><td rowspan="1" colspan="1">&#x02212;5.81&#x000b1;1.20</td><td rowspan="1" colspan="1">&#x02212;8.73&#x000b1;1.36</td></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02264;0.001</td><td rowspan="1" colspan="1">&#x02264;0.0001</td><td rowspan="1" colspan="1">&#x02264;0.0001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02264;0.0001</td><td rowspan="1" colspan="1">&#x02264;0.0001</td><td rowspan="1" colspan="1">&#x02264;0.0001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02264;0.0001</td><td rowspan="1" colspan="1">&#x02264;0.0001</td><td rowspan="1" colspan="1">&#x02264;0.0001</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold> Values are expressed as mean &#x000b1; SD. Within groups compared to baseline: 4 weeks &#x02013; A p&#x02264;0.001, B p&#x02264;0.0001, C p&#x02264;0.0001; 8 weeks &#x02013; A, B and C p&#x02264;0.0001; 12 weeks &#x02013; A, B and C p&#x02264;0.0001. Between groups: 4 weeks &#x02013; B vs A p&#x02264;0.001, C vs A and C vs B p&#x02264;0.0001; 8 weeks &#x02013; B vs A, C vs A and C vs B p&#x02264;0.0001; 12 weeks &#x02013; B vs A, C vs A and C vs B p&#x02264;0.0001.</p></fn></table-wrap-foot></table-wrap>
</p><p>The biomarkers of oxidative stress showed improvement at 12 weeks in all the groups. As depicted in <xref rid="T0003" ref-type="table">Table 3</xref>, statistically significant differences in mean percentage change were seen for MDA, NO and GSH. Similar results were obtained for the markers of inflammation at 12 weeks (hsCRP, ICAM-1, VCAM-1 and ET-1). Group B treatment was better than Group A (p&#x0003c;0.0001), while Group C treatment was more efficacious than the other groups (p&#x0003c;0.0001). The level of significance between Groups C and B in improving the ET-1 levels was p&#x0003c;0.05.<table-wrap id="T0003" orientation="landscape" position="float"><label>Table 3</label><caption><p>Effect of Treatment on Biomarkers of Oxidative Stress, Systemic Inflammation and Vascular Inflammation at 12 Weeks</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameter</th><th colspan="3" rowspan="1">Fish Oil 2000 mg (Group A) (n=19)</th><th colspan="3" rowspan="1">Fish Oil 2000 mg + PCC 10 mg (Group B) (n=20)</th><th colspan="3" rowspan="1">Fish Oil 2000 mg + PCC 20 mg (Group C) (n=20)</th></tr><tr><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Mean % Change</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Mean % Change</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Mean % Change</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">MDA (nM/mL)</td><td rowspan="1" colspan="1">3.77&#x000b1;0.16</td><td rowspan="1" colspan="1">3.74&#x000b1;0.16</td><td rowspan="1" colspan="1">&#x02212;0.88&#x000b1;1.24</td><td rowspan="1" colspan="1">3.80&#x000b1;0.26</td><td rowspan="1" colspan="1">3.56&#x000b1;0.27</td><td rowspan="1" colspan="1">&#x02212;6.36&#x000b1;2.12</td><td rowspan="1" colspan="1">3.67&#x000b1;0.39</td><td rowspan="1" colspan="1">2.89&#x000b1;0.34</td><td rowspan="1" colspan="1">&#x02212;21.29&#x000b1;4.03</td></tr><tr><td rowspan="1" colspan="1">NO (&#x000b5;M/L)</td><td rowspan="1" colspan="1">30.60&#x000b1;3.18</td><td rowspan="1" colspan="1">32.12&#x000b1;3.40</td><td rowspan="1" colspan="1">+4.94&#x000b1;1.29</td><td rowspan="1" colspan="1">31.65&#x000b1;2.80</td><td rowspan="1" colspan="1">38.37&#x000b1;2.68</td><td rowspan="1" colspan="1">+21.56&#x000b1;6.17</td><td rowspan="1" colspan="1">28.98&#x000b1;2.93</td><td rowspan="1" colspan="1">40.01&#x000b1;2.53</td><td rowspan="1" colspan="1">+38.79&#x000b1;9.41</td></tr><tr><td rowspan="1" colspan="1">GSH (&#x000b5;M/L)</td><td rowspan="1" colspan="1">568.93&#x000b1;5.91</td><td rowspan="1" colspan="1">583.95&#x000b1;6.53</td><td rowspan="1" colspan="1">+2.64&#x000b1;0.70</td><td rowspan="1" colspan="1">564.89&#x000b1;11.04</td><td rowspan="1" colspan="1">639.88&#x000b1;9.42</td><td rowspan="1" colspan="1">+13.30&#x000b1;1.99</td><td rowspan="1" colspan="1">553.82&#x000b1;8.18</td><td rowspan="1" colspan="1">677.99&#x000b1;10.19</td><td rowspan="1" colspan="1">+22.44&#x000b1;2.33</td></tr><tr><td rowspan="1" colspan="1">hsCRP (mg/L)</td><td rowspan="1" colspan="1">3.15&#x000b1;0.64</td><td rowspan="1" colspan="1">3.09&#x000b1;0.62</td><td rowspan="1" colspan="1">&#x02212;2.09&#x000b1;1.07</td><td rowspan="1" colspan="1">3.08&#x000b1;0.68</td><td rowspan="1" colspan="1">2.19&#x000b1;0.6</td><td rowspan="1" colspan="1">&#x02212;28.12&#x000b1;17.70</td><td rowspan="1" colspan="1">3.06&#x000b1;0.83</td><td rowspan="1" colspan="1">1.13&#x000b1;0.47</td><td rowspan="1" colspan="1">&#x02212;63.40&#x000b1;11.75</td></tr><tr><td rowspan="1" colspan="1">ICAM-1 (ng/mL)</td><td rowspan="1" colspan="1">763.21&#x000b1;165.03</td><td rowspan="1" colspan="1">708.89&#x000b1;152.64</td><td rowspan="1" colspan="1">&#x02212;6.91&#x000b1;5.52</td><td rowspan="1" colspan="1">799.15&#x000b1;219.40</td><td rowspan="1" colspan="1">650.50&#x000b1;176.62</td><td rowspan="1" colspan="1">&#x02212;18.34&#x000b1;6.55</td><td rowspan="1" colspan="1">769.40&#x000b1;215.48</td><td rowspan="1" colspan="1">534.65&#x000b1;119.95</td><td rowspan="1" colspan="1">&#x02212;29.21&#x000b1;8.34</td></tr><tr><td rowspan="1" colspan="1">VCAM-1 (ng/mL)</td><td rowspan="1" colspan="1">921.73&#x000b1;250.08</td><td rowspan="1" colspan="1">858.56&#x000b1;210.38</td><td rowspan="1" colspan="1">&#x02212;5.85&#x000b1;8.31</td><td rowspan="1" colspan="1">988.32&#x000b1;174.73</td><td rowspan="1" colspan="1">763.56&#x000b1;95.06</td><td rowspan="1" colspan="1">&#x02212;22.04&#x000b1;5.59</td><td rowspan="1" colspan="1">942.31&#x000b1;134.95</td><td rowspan="1" colspan="1">570.39&#x000b1;63.97</td><td rowspan="1" colspan="1">&#x02212;38.64&#x000b1;8.99</td></tr><tr><td rowspan="1" colspan="1">ET-1 (pg/mL)</td><td rowspan="1" colspan="1">5.03&#x000b1;0.72</td><td rowspan="1" colspan="1">4.56&#x000b1;0.70</td><td rowspan="1" colspan="1">&#x02212;9.43&#x000b1;4.48</td><td rowspan="1" colspan="1">5.23&#x000b1;0.54</td><td rowspan="1" colspan="1">4.24&#x000b1;0.54</td><td rowspan="1" colspan="1">&#x02212;19.19&#x000b1;2.56</td><td rowspan="1" colspan="1">5.16&#x000b1;0.78</td><td rowspan="1" colspan="1">3.87&#x000b1;0.40</td><td rowspan="1" colspan="1">&#x02212;24.19&#x000b1;9.03</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold> Values are expressed as mean &#x000b1; SD. Within groups compared to baseline: MDA: A p&#x02264;0.01, B and C p&#x02264;0.0001; NO: A, B and C p&#x02264;0.0001; GSH: A, B and C p&#x02264;0.0001; hsCRP: A, B and C p&#x02264;0.0001; ICAM-1: A, B and C p&#x02264;0.0001; VCAM-1: A p&#x02264;0.05, B and C p&#x02264;0.0001; ET-1: A, B and C p&#x02264;0.0001. Between groups: MDA: B vs A, C vs A and C vs B p&#x02264;0.0001; NO: B vs A, C vs A and C vs B p&#x02264;0.0001; GSH: B vs A, C vs A and C vs B p&#x02264;0.0001; hsCRP: B vs A, C vs A and C vs B p&#x02264;0.0001; ICAM-1: B vs A, C vs A and C vs B p&#x02264;0.0001; VCAM-1: B vs A, C vs A and C vs B p&#x02264;0.0001; ET-1: B vs A and C vs A p&#x02264;0.0001, C vs B p&#x02264;0.05.</p></fn></table-wrap-foot></table-wrap>
</p><p>As shown in <xref rid="T0004" ref-type="table">Table 4</xref>, at 12 weeks, statistical significance was seen with all three groups in mean percentage change in TC (&#x02212;7.53%, &#x02212;14.62%, &#x02212;23.68 in Groups A, B, C, respectively), HDL (4.74%, 14.14%, 25.11%), LDL-C (&#x02212;11.06%, &#x02212;26.14%, &#x02212;37.20%), VLDL (&#x02212;10.23%, &#x02212;15.98%, &#x02212;28.06%) and TGs (&#x02212;10.10%, &#x02212;15.00%, &#x02212;28.11%). The significance at the end of 12 weeks for Groups A, B and C was p&#x0003c;0.0001 compared to baseline. Between-group analysis showed Group C to be better than Group A (p&#x0003c;0.0001) and Group B (p&#x0003c;0.0001) in improving all the parameters except LDL-C, where there was no significant difference between Groups C and B. No effect was recorded on platelet aggregation in any of the groups.<table-wrap id="T0004" orientation="landscape" position="float"><label>Table 4</label><caption><p>Effect of Treatment on Lipid Profile at 12 Weeks</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameter</th><th colspan="3" rowspan="1">Fish Oil 2000 mg (Group A) (n=19)</th><th colspan="3" rowspan="1">Fish Oil 2000 mg + PCC 10 mg (Group B) (n=20)</th><th colspan="3" rowspan="1">Fish Oil 2000 mg + PCC 20 mg (Group C) (n=20)</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Mean % Change</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Mean % Change</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Mean % Change</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td rowspan="1" colspan="1">192.53&#x000b1;17.53</td><td rowspan="1" colspan="1">177.79&#x000b1;16.27</td><td rowspan="1" colspan="1">&#x02212;7.53&#x000b1;5.39</td><td rowspan="1" colspan="1">185.15&#x000b1;13.22</td><td rowspan="1" colspan="1">158.15&#x000b1;18.36</td><td rowspan="1" colspan="1">&#x02212;14.62&#x000b1;7.26</td><td rowspan="1" colspan="1">195.10&#x000b1;23.95</td><td rowspan="1" colspan="1">148.75&#x000b1;20.34</td><td rowspan="1" colspan="1">&#x02212;23.68&#x000b1;6.41</td></tr><tr><td rowspan="1" colspan="1">HDL-C (mg/dL)</td><td rowspan="1" colspan="1">40.79&#x000b1;3.79</td><td rowspan="1" colspan="1">42.68&#x000b1;3.68</td><td rowspan="1" colspan="1">4.74&#x000b1;2.66</td><td rowspan="1" colspan="1">40.55&#x000b1;3.56</td><td rowspan="1" colspan="1">46.55&#x000b1;4.20</td><td rowspan="1" colspan="1">14.14&#x000b1;4.57</td><td rowspan="1" colspan="1">38.55&#x000b1;3.85</td><td rowspan="1" colspan="1">48.20&#x000b1;4.79</td><td rowspan="1" colspan="1">25.11&#x000b1;4.59</td></tr><tr><td rowspan="1" colspan="1">LDL-C (mg/dL)</td><td rowspan="1" colspan="1">109.53&#x000b1;17.50</td><td rowspan="1" colspan="1">97.00&#x000b1;15.99</td><td rowspan="1" colspan="1">&#x02212;11.06&#x000b1;10.34</td><td rowspan="1" colspan="1">102.70&#x000b1;14.39</td><td rowspan="1" colspan="1">76.40&#x000b1;20.04</td><td rowspan="1" colspan="1">&#x02212;26.14&#x000b1;13.63</td><td rowspan="1" colspan="1">105.90&#x000b1;18.71</td><td rowspan="1" colspan="1">70.80&#x000b1;20.87</td><td rowspan="1" colspan="1">&#x02212;37.20&#x000b1;11.96</td></tr><tr><td rowspan="1" colspan="1">VLDL-C (mg/dL)</td><td rowspan="1" colspan="1">39.95&#x000b1;2.39</td><td rowspan="1" colspan="1">35.89&#x000b1;2.96</td><td rowspan="1" colspan="1">&#x02212;10.23&#x000b1;3.06</td><td rowspan="1" colspan="1">41.90&#x000b1;2.51</td><td rowspan="1" colspan="1">35.20&#x000b1;2.82</td><td rowspan="1" colspan="1">&#x02212;15.98&#x000b1;4.60</td><td rowspan="1" colspan="1">41.35&#x000b1;2.54</td><td rowspan="1" colspan="1">29.75&#x000b1;2.12</td><td rowspan="1" colspan="1">&#x02212;28.06&#x000b1;2.54</td></tr><tr><td rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td rowspan="1" colspan="1">199.95&#x000b1;12.00</td><td rowspan="1" colspan="1">179.95&#x000b1;15.19</td><td rowspan="1" colspan="1">&#x02212;10.10&#x000b1;3.08</td><td rowspan="1" colspan="1">209.20&#x000b1;12.51</td><td rowspan="1" colspan="1">177.95&#x000b1;14.18</td><td rowspan="1" colspan="1">&#x02212;15.00&#x000b1;3.24</td><td rowspan="1" colspan="1">206.95&#x000b1;13.20</td><td rowspan="1" colspan="1">148.75&#x000b1;10.02</td><td rowspan="1" colspan="1">&#x02212;28.11&#x000b1;2.21</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold> Values are expressed as mean &#x000b1; SD. Within groups compared to baseline: TC, HDL-C, LDL-C, VLDL-C, TG: A, B and C p&#x02264;0.0001. Between groups: TC: B vs A p&#x02264;0.01, C vs B and C vs A p&#x02264;0.0001; HDL-C: B vs A, C vs B and C vs A p&#x02264;0.0001; LDL-C: B vs A p&#x02264;0.001, C vs A p&#x02264;0.0001, C vs B ns; VLDL-C: B vs A, C vs B and C vs A p&#x02264;0.0001; TG: B vs A, C vs B and C vs A p&#x02264;0.0001.</p><p><bold>Abbreviation:</bold> ns, not significant.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="T0005" orientation="portrait" position="float"><label>Table 5</label><caption><p>Effect of Treatment on HbA1c at 12 Weeks</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Group</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">12 Weeks</th><th rowspan="1" colspan="1">Mean % Change</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Fish oil 2000 mg + placebo (A)</td><td rowspan="1" colspan="1">6.9&#x000b1;0.4</td><td rowspan="1" colspan="1">7.0&#x000b1;0.4</td><td rowspan="1" colspan="1">+2.5&#x000b1;4.3</td></tr><tr><td rowspan="1" colspan="1">Fish oil 2000 mg + PCC 200 &#x000b5;g (B)</td><td rowspan="1" colspan="1">7.1&#x000b1;0.6</td><td rowspan="1" colspan="1">6.8&#x000b1;0.6</td><td rowspan="1" colspan="1">&#x02212;3.2&#x000b1;2.7</td></tr><tr><td rowspan="1" colspan="1">Fish oil 2000 mg + PCC 400 &#x000b5;g (C)</td><td rowspan="1" colspan="1">7.3&#x000b1;0.6</td><td rowspan="1" colspan="1">6.8&#x000b1;0.6</td><td rowspan="1" colspan="1">&#x02212;6.4&#x000b1;2.2</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold> Values are expressed as mean &#x000b1; SD. Within groups compared to baseline: Group A ns, Groups B and C p&#x02264;0.0001. Between groups: A vs B, A vs C p&#x02264;0.0001, B vs C p&#x02264;0.05.</p></fn><fn><p><bold>Abbreviation:</bold> ns, not significant.</p></fn></table-wrap-foot></table-wrap>
</p><p>A statistically significant (p&#x0003c;0.0001) decrease in HbA1c after 12 weeks of treatment was seen in Groups C (from 7.3% to 6.8%) and B (from 7.1% to 6.8%) (Table 5). Group A tended to show an increase in HbA1c, while both Groups B and C had decreased HbA1c, by a modest 3.2% and 6.4%, respectively. Between-group analysis showed Group C to be better than both Group A (p&#x0003c;0.0001) and Group B (p&#x0003c;0.05).</p><p>All safety hematological and biochemical parameters were found to be within normal limits in all groups at the end of 12 weeks. Only one subject in Group C complained of nausea, which subsided with symptomatic treatment. However, no subject in any of the groups dropped out of the study owing to adverse events.</p></sec><sec id="S0004"><title>Discussion</title><p>Significant, though modest, improvement in endothelial function (RI), biomarkers of oxidative stress, systemic and vascular inflammation, and lipid profile was seen with fish oil alone. Addition of PCC, especially at 20 mg dose (400 &#x000b5;g of Cr<sup>3+</sup>), significantly increased the efficacy of fish oil.</p><p>In a 12-week study by Wong et al<xref rid="CIT0050" ref-type="bibr">50</xref> on T2DM patients, no improvement in EnD was seen with &#x003c9;-3FA (4 g/day). Similarly, Siniarski et al<xref rid="CIT0051" ref-type="bibr">51</xref> reported no improvement in EnD with 1000mg EPA plus 1000mg DHA taken per day. In a previous study<xref rid="CIT0052" ref-type="bibr">52</xref> in our department, we showed the beneficial effect of PCC on endothelial function in T2DM patients. In the present study, we observed that addition of PCC, especially at 20 mg (400 &#x000b5;g of Cr<sup>3+</sup>), significantly complemented the efficacy of &#x003c9;-3FA in improving EnD in T2DM subjects. We presume that the highly significant improvement in endothelial function in the present study is associated with the combining of fish oil with PCC.</p><p>MDA is a by-product formed by lipid peroxidation due to free radical generation, whereas GSH is an endogenous antioxidant and is known to minimize lipid peroxidation resulting from excessive ROS.<xref rid="CIT0053" ref-type="bibr">53</xref> In our study we have shown statistically significant improvement in the levels of MDA and GSH in all three treatment groups. Although the effect of Group A treatment on MDA and GSH was modest, the endogenous antioxidant power increased significantly with the addition of PCC to fish oil. Group C showed significantly better results than Groups A and B. The results in the present study are similar to those of Shidfar et al,<xref rid="CIT0054" ref-type="bibr">54</xref> who related the potential mechanism for the decrease in MDA to the inhibitory effect of &#x003c9;-3FAs on the pro-oxidant enzyme phospholipase A2 and stimulation of antioxidant enzymes. The improvement in GSH levels could be due to the positive effect of &#x003c9;-3FAs in improving the levels of glutathione reductase.<xref rid="CIT0055" ref-type="bibr">55</xref> So, in our study we assume that the combination of fish oil with PCC is the reason for the better results compared to fish oil alone.</p><p>NO has an important role in the determination of vascular health. Impaired bioavailability of NO represents an essential feature of EnD.<xref rid="CIT0056" ref-type="bibr">56</xref> In a 12-week study by Asemi et al,<xref rid="CIT0057" ref-type="bibr">57</xref> &#x003c9;-3FA alone and its combination with alpha-tocopherol significantly increased NO levels. This was attributed to direct and indirect effects of &#x003c9;-3FA on the arterial wall. In the present study, after 12 weeks of treatment, levels of NO increased significantly in all the groups. Group C showed significantly better results than both Groups A and B, substantiating that endothelial function had indeed improved very significantly with the addition of PCC to fish oil. The probable mechanism in improved NO levels could be as reported by Asemi et al.<xref rid="CIT0057" ref-type="bibr">57</xref> We assume that the combination of fish oil with PCC is more beneficial than fish oil alone.</p><p>Yamada et al,<xref rid="CIT0058" ref-type="bibr">58</xref> in their study on metabolic syndrome subjects, reported that EPA improved the levels of the adhesion molecules ICAM-1 and VCAM-1. Their results are in concurrence with the highly significant reductions in ICAM-1, VCAM-1 and ET-1 in all three treatment groups in our study, with the best improvement seen in Group C. NO, a vasodilator, seems to have anti-inflammatory properties and thus decreases ICAM-1 and VCAM-1 expression.<xref rid="CIT0059" ref-type="bibr">59</xref> In our study, as mentioned in the previous paragraph, a significant improvement in NO levels was seen. The positive effect of &#x003c9;-3FA on NO levels, along with the inhibitory effect on endothelial expression of adhesion molecules, is the possible mechanism of action of &#x003c9;-3FAs.<xref rid="CIT0060" ref-type="bibr">60</xref> The addition of PCC to fish oil in our study seems to have provided a highly significant response on biomarkers of vascular inflammation, compared to fish oil given alone.</p><p>C-reactive protein is a robust biomarker of chronic systemic inflammation. Higher values of hsCRP are associated with metabolic disorders and its components.<xref rid="CIT0061" ref-type="bibr">61</xref> Schiano et al<xref rid="CIT0062" ref-type="bibr">62</xref> and Mackay et al<xref rid="CIT0063" ref-type="bibr">63</xref> reported no change in hsCRP and platelet aggregation with &#x003c9;-3FAs. In previous studies<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0064" ref-type="bibr">64</xref> carried out in our department, we reported the beneficial effects of PCC and its constituent materials on hsCRP. In the present study, we observed a significant change in hsCRP values at 12 weeks in all three treatment groups. Group C showed more robust improvement compared to the other two groups. We presume that this was due to the addition of PCC. No change in platelet aggregation, akin to the study by Mackay et al,<sup>63</sup> was seen in this study.</p><p>In a study by Harris et al<xref rid="CIT0065" ref-type="bibr">65</xref> and Koski RR<xref rid="CIT0066" ref-type="bibr">66</xref> in hypertriglyceridemia subjects, fish oil (OMACOR &#x02013; a prescription product) improved TG, TC, VLDL-C and HDL-C levels significantly, but increased the LDL-C levels. In our study, improvement in LDL-C was observed along with other parameters mentioned in the above studies.<xref rid="CIT0065" ref-type="bibr">65</xref>,<xref rid="CIT0066" ref-type="bibr">66</xref> In a similar study by Bays et al,<xref rid="CIT0067" ref-type="bibr">67</xref> 4g/day of &#x003c9;-3FA (VASCEPA containing purified EPA and no DHA) significantly improved TGs without significantly increasing the LDL-C levels. Katoka Y et al,<xref rid="CIT0068" ref-type="bibr">68</xref>&#x000a0;also reported the same. We observed a decrease in the LDL-C levels in our study. A study by Cicero et al<xref rid="CIT0069" ref-type="bibr">69</xref> in hypertriglyceridemia subjects reported improvements in TG and HDL-C levels while no significant difference was seen in TC and LDL-C levels. Sawada et al,<xref rid="CIT0070" ref-type="bibr">70</xref> in subjects with diminished glucose metabolism and coronary artery disease, reported improvement in fasting TG levels and TG/HDL-C ratio. They related this to improved endothelial function. In our study we observed significant improvements in all the parameters of the lipid profile in the three treatment groups. The most significant improvement, seen in Group C, can be attributed to the addition of PCC.</p><p>A meta-analysis of 83 randomized trials by Brown et al<xref rid="CIT0071" ref-type="bibr">71</xref> showed that increasing omega-3, omega-6 or total polyunsaturated fatty acids has little or no effect on the prevention and treatment of T2DM. In our study there was a significant improvement in HbA1c levels in Groups B and C, while Group A showed no improvement. The improvement in Groups B and C can be attributed to PCC.</p></sec><sec id="S0005"><title>Conclusion</title><p>It can be concluded from this study in T2DM subjects that fish oil by itself, at a dose of 2000 mg/day, containing 600 mg of EPA plus 400 mg of DHA, led to a modest but statistically significant improvement in the lipid profile, including the TG levels and the adhesion molecules, but only small effects on EnD, oxidative stress biomarkers and the systemic inflammation biomarker, and no effect on HbA1c. However, addition of PCC to fish oil, especially at 20 mg dose, significantly and robustly improved EnD, the biomarkers of oxidative stress, systemic inflammation and the lipid profile, but HbA1c only modestly. It is noteworthy that all three groups showed significant changes in lipid profile, although the most significant improvement in lipid profile was obtained with the group receiving fish oil plus 20 mg PCC. Furthermore, these results were obtained with only 2 g/day of fish oil. This study provides initial evidence that the addition of PCC (Crominex 3+) to fish oil significantly improved the cardiovascular health benefits of fish oil. The strengths of the study include that we evaluated the improvement in EnD by estimating the RI and biomarkers MDA, NO and GSH. We also evaluated the effect on the vascular inflammation biomarkers ICAM-1, VCAM-1 and ET-1, and the systemic inflammation biomarker hsCRP. A limitation of our study is that we did not include a placebo group.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are indebted to Natreon, Inc, USA, for arranging the study medications and kits for biomarkers, and study coordinator Mr Muralidhar. We express gratitude to Dr Y.S.N. Raju, Professor of General Medicine, NIMS, for his clinical support.</p></ack><sec id="S0006"><title>Abbreviations</title><p>ALT, alanine transaminase; AST, aspartate transaminase; CHD, coronary heart disease; CRP, C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EnD, endothelial dysfunction; EPA, eicosapentaenoic acid; ET-1, endothelin-1; GSH, glutathione; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; ICAM-1, intercellular adhesion molecule-1; LDL-C, low-density lipoprotein cholesterol; MDA, malondialdehyde; MRIFT, Multiple Risk Factor Intervention Trial; NO, nitric oxide; PCC, proprietary chromium complex; ROS, reactive oxygen species; RI, reflection index; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; T2DM, type 2 diabetes mellitus; VCAM-1, vascular cell adhesion molecule-1; VLDL-C, very low-density lipoprotein cholesterol; &#x003c9;-3FA, omega-3 fatty acid.</p></sec><sec id="S0007"><title>Data Sharing Statement</title><p>The data will be handled on a case-by-case basis as per institutional policy.</p></sec><sec id="S0008"><title>Ethics and Consent</title><p>The present study was started after obtaining approval from NIMS &#x02013; Institutional Ethics Committee, review letter no. EC/NIMS/1978/2017; ESGS no. 520/2017. Prior to participation in the study, all subjects had provided written informed consent.</p><p>Registration of the trial: The study has been registered with Clinical Trials Registry &#x02013; India (CTRI). Registration number: CTRI/2018/05/013547 [Registered on: 01/05/2018] trial registered retrospectively.</p></sec><sec id="S0009" sec-type="COI-statement"><title>Disclosure</title><p>The authors declare no competing interests.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source><italic toggle="yes">World Health Statistics. Department of Measurement &#x00026; Health Information Systems of the Information, Evidence and Research Cluster</italic></source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO Press</publisher-name>; <year>2018</year>:<fpage>7</fpage>.</mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Einarson</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>Acs</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ludwig</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Panton</surname>
<given-names>UH</given-names></string-name>. <article-title>Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007&#x02013;2017</article-title>. <source><italic toggle="yes">Cardiovasc Diabetol</italic></source>. <year>2018</year>;<volume>17</volume>(<issue>1</issue>):<fpage>83</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12933-018-0728-6</pub-id><pub-id pub-id-type="pmid">29884191</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Strain</surname>
<given-names>WD</given-names></string-name>, <string-name><surname>Pald&#x000e1;nius</surname>
<given-names>PM</given-names></string-name>. <article-title>Diabetes, cardiovascular disease and the microcirculation</article-title>. <source><italic toggle="yes">Cardiovasc Diabetol</italic></source>. <year>2018</year>;<volume>17</volume>(<issue>1</issue>):<fpage>57</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12933-018-0703-2</pub-id><pub-id pub-id-type="pmid">29669543</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Stehouwer</surname>
<given-names>CD</given-names></string-name>, <string-name><surname>Lambert</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Donker</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>van Hinsbergh</surname>
<given-names>VW</given-names></string-name>. <article-title>Endothelial dysfunction and pathogenesis of diabetic angiopathy</article-title>. <source><italic toggle="yes">Cardiovasc Res</italic></source>. <year>1997</year>;<volume>34</volume>(<issue>1</issue>):<fpage>55</fpage>&#x02013;<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0008-6363(96)00272-6</pub-id><pub-id pub-id-type="pmid">9217873</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Pandolfi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>De Filippis</surname>
<given-names>EA</given-names></string-name>. <article-title>Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications</article-title>. <source><italic toggle="yes">Genes Nutr</italic></source>. <year>2007</year>;<volume>2</volume>(<issue>2</issue>):<fpage>195</fpage>&#x02013;<lpage>208</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12263-007-0050-5</pub-id><pub-id pub-id-type="pmid">18850175</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Schofield</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Balakrishna</surname>
<given-names>PR</given-names></string-name>, <string-name><surname>Malik</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Soran</surname>
<given-names>H</given-names></string-name>. <article-title>Diabetes dyslipidemia</article-title>. <source><italic toggle="yes">Diabetes Ther</italic></source>. <year>2016</year>;<volume>7</volume>(<issue>2</issue>):<fpage>203</fpage>&#x02013;<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13300-016-0167-x</pub-id><pub-id pub-id-type="pmid">27056202</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Kolluru</surname>
<given-names>GK</given-names></string-name>, <string-name><surname>Bir</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Kevil</surname>
<given-names>CG</given-names></string-name>.<article-title>Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing</article-title>. <source><italic toggle="yes">Int J Vasc Med</italic></source>.<year>2012</year>;<volume>2012</volume>:<fpage>1</fpage>&#x02013;<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1155/2012/918267</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Bret&#x000f3;n-Romero</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Holbrook</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Endothelial dysfunction in human diabetes is mediated by Wnt5a-JNK signaling</article-title>. <source><italic toggle="yes">Arterioscler Thromb Vasc Biol</italic></source>. <year>2016</year>;<volume>36</volume>(<issue>3</issue>):<fpage>561</fpage>&#x02013;<lpage>569</lpage>. doi:<pub-id pub-id-type="doi">10.1161/ATVBAHA.115.306578</pub-id><pub-id pub-id-type="pmid">26800561</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Park</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>WJ</given-names></string-name>. <article-title>Endothelial dysfunction: clinical implications in cardiovascular disease and therapeutic approaches</article-title>. <source><italic toggle="yes">J Korean Med Sci</italic></source>. <year>2015</year>;<volume>30</volume>(<issue>9</issue>):<fpage>1213</fpage>&#x02013;<lpage>1225</lpage>. doi:<pub-id pub-id-type="doi">10.3346/jkms.2015.30.9.1213</pub-id><pub-id pub-id-type="pmid">26339159</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Daiber</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Steven</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Weber</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Targeting vascular (endothelial) dysfunction</article-title>. <source><italic toggle="yes">Br J Pharmacol</italic></source>. <year>2017</year>;<volume>174</volume>(<issue>12</issue>):<fpage>1591</fpage>&#x02013;<lpage>1619</lpage>.<pub-id pub-id-type="pmid">27187006</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Yamazaki</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hitomi</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Nishiyama</surname>
<given-names>A</given-names></string-name>. <article-title>Hypertension with diabetes mellitus complications</article-title>. <source><italic toggle="yes">Hypertens Res</italic></source>. <year>2018</year>;<volume>41</volume>:<fpage>147</fpage>&#x02013;<lpage>156</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41440-017-0008-y</pub-id><pub-id pub-id-type="pmid">29353881</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Neaton</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Blackburn</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Jacobs</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kuller</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Sherwin</surname>
<given-names>R</given-names></string-name>. <article-title>Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Multiple risk factor intervention trial research group</article-title>. <source><italic toggle="yes">Arch Intern Med</italic></source>. <year>1992</year>;<volume>152</volume>(<issue>7</issue>):<fpage>1490</fpage>&#x02013;<lpage>1500</lpage>.<pub-id pub-id-type="pmid">1627030</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Aung</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Halsey</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kromhout</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 Individuals</article-title>. <source><italic toggle="yes">JAMA Cardiol</italic></source>. <year>2018</year>;<volume>3</volume>(<issue>3</issue>):<fpage>225</fpage>&#x02013;<lpage>233</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamacardio.2017.5205</pub-id><pub-id pub-id-type="pmid">29387889</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Zivkovic</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Telis</surname>
<given-names>N</given-names></string-name>, <string-name><surname>German</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Hammock</surname>
<given-names>BD</given-names></string-name>. <article-title>Dietary omega-3 fatty acids aid in the modulation of inflammation and metabolic health</article-title>. <source><italic toggle="yes">Calif Agric (Berkeley)</italic></source>. <year>2011</year>;<volume>65</volume>(<issue>3</issue>):<fpage>106</fpage>&#x02013;<lpage>111</lpage>. doi:<pub-id pub-id-type="doi">10.3733/ca.v065n03p106</pub-id><pub-id pub-id-type="pmid">24860193</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>
<given-names>YF</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>HF</given-names></string-name>, <string-name><surname>Hou</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>YH</given-names></string-name>. <article-title>Effect of omega-3 fatty acid supplementation on cancer incidence, non-vascular death and total mortality: a meta-analysis of randomized controlled trials</article-title>. <source><italic toggle="yes">BMC Public Health</italic></source>. <year>2014</year>;<volume>14</volume>:<fpage>204</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2458-14-204</pub-id><pub-id pub-id-type="pmid">24568238</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Din</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Sarma</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Harding</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Lyall</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Newby</surname>
<given-names>DE</given-names></string-name>, <string-name><surname>Flapan</surname>
<given-names>AD</given-names></string-name>. <article-title>Effect of &#x003c9;-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in patients with a previous myocardial infarction: a randomised controlled trial</article-title>. <source><italic toggle="yes">BMJ Open</italic></source>. <year>2013</year>;<volume>3</volume>:<fpage>e003054</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2013-003054</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Chan</surname>
<given-names>DC</given-names></string-name>, <string-name><surname>Watts</surname>
<given-names>GF</given-names></string-name>, <string-name><surname>Barrett</surname>
<given-names>PHR</given-names></string-name>, <string-name><surname>Beilin</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>TA</given-names></string-name>. <article-title>Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity</article-title>. <source><italic toggle="yes">Clin Chem</italic></source>. <year>2002</year>;<volume>48</volume>(<issue>6</issue>):<fpage>877</fpage>&#x02013;<lpage>883</lpage>.<pub-id pub-id-type="pmid">12029003</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Kromhout</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Yasuda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Geleijnse</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Shimokawa</surname>
<given-names>H</given-names></string-name>. <article-title>Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?</article-title>
<source><italic toggle="yes">Eur Heart J</italic></source>. <year>2012</year>;<volume>33</volume>(<issue>4</issue>):<fpage>436</fpage>&#x02013;<lpage>443</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehr362</pub-id><pub-id pub-id-type="pmid">21933782</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Aucoin</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cooley</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Knee</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Fish-derived omega-3 fatty acids and prostate cancer: a systematic review</article-title>. <source><italic toggle="yes">Integr Cancer Ther</italic></source>. <year>2017</year>;<volume>16</volume>:<fpage>32</fpage>&#x02013;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1534735416656052</pub-id><pub-id pub-id-type="pmid">27365385</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Kwak</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Myung</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>YJ</given-names></string-name>, <string-name><surname>Seo</surname>
<given-names>HG</given-names></string-name>; <collab>Korean Meta-analysis Study Group</collab>. <article-title>Efficacy of omega-3 Fatty acid supplements (Eicosapentaenoic acid and Docosahexaenoic acid) in the secondary prevention of cardiovascular disease</article-title>. <source><italic toggle="yes">Arch Intern Med</italic></source>. <year>2012</year>;<volume>172</volume>(<issue>9</issue>):<fpage>686</fpage>&#x02013;<lpage>694</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinternmed.2012.262</pub-id><pub-id pub-id-type="pmid">22493407</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Grosso</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Galvano</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Marventano</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Omega-3 fatty acids and depression: scientific evidence and biological mechanisms</article-title>. <source><italic toggle="yes">Oxid Med Cell Longev</italic></source>. <year>2014</year>;<fpage>313570</fpage>.<pub-id pub-id-type="pmid">24757497</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Weylandt</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Serini</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>YQ</given-names></string-name>, et al. <article-title>Omega-3 polyunsaturated fatty acids: the way forward in times of mixed evidence</article-title>. <source><italic toggle="yes">Biomed Res Int</italic></source>. <year>2015</year>;<fpage>143109</fpage>.<pub-id pub-id-type="pmid">26301240</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Siscovick</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Barringer</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Fretts</surname>
<given-names>AM</given-names></string-name>, et al. <article-title>Omega-3 polyunsaturated fatty acid (Fish oil) supplementation and the prevention of clinical cardiovascular disease. A science advisory from the American Heart Association</article-title>. <source><italic toggle="yes">Circulation</italic></source>. <year>2017</year>;<volume>135</volume>(<issue>15</issue>):<fpage>e867</fpage>&#x02013;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIR.0000000000000482</pub-id><pub-id pub-id-type="pmid">28289069</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Nutalapati</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chiranjeevi</surname>
<given-names>UK</given-names></string-name>, <string-name><surname>Kishan</surname>
<given-names>PV</given-names></string-name>, <string-name><surname>Kiran</surname>
<given-names>KK</given-names></string-name>, <string-name><surname>Pingali</surname>
<given-names>U</given-names></string-name>. <article-title>A randomized, double-blind, placebo-controlled, parallel group clinical study to evaluate the analgesic effect of aqueous extract of terminalia chebula, a proprietary chromium complex, and their combination in subjects with joint discomfort</article-title>. <source><italic toggle="yes">Asian J Pharm Clin Res</italic></source>. <year>2016</year>;<volume>9</volume>(<issue>3</issue>):<fpage>264</fpage>&#x02013;<lpage>269</lpage>.</mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Hua</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Clark</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ren</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Nair</surname>
<given-names>S</given-names></string-name>. <article-title>Molecular mechanisms of chromium in alleviating insulin resistance</article-title>. <source><italic toggle="yes">J Nutr Biochem</italic></source>. <year>2012</year>;<volume>23</volume>(<issue>4</issue>):<fpage>313</fpage>&#x02013;<lpage>319</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jnutbio.2011.11.001</pub-id><pub-id pub-id-type="pmid">22423897</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Bai</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Xun</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Morris</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jacobs</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>K</given-names></string-name>, <string-name><surname>He</surname>
<given-names>K</given-names></string-name>. <article-title>Chromium exposure and incidence of metabolic syndrome among American young adults over a 23-year follow-up: the CARDIA trace element study</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2015</year>;<volume>5</volume>:<fpage>15606</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep15606</pub-id><pub-id pub-id-type="pmid">26489690</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Usharani</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Fatima</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Muralidhar</surname>
<given-names>N</given-names></string-name>. <article-title>Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study</article-title>. <source><italic toggle="yes">Diabetes Metab Syndr Obes</italic></source>. <year>2013</year>;<volume>6</volume>:<fpage>275</fpage>&#x02013;<lpage>284</lpage>. doi:<pub-id pub-id-type="doi">10.2147/DMSO.S46341</pub-id><pub-id pub-id-type="pmid">23935377</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Biswas</surname>
<given-names>TK</given-names></string-name>, <string-name><surname>Chakrabarty</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pandit</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jana</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Dey</surname>
<given-names>SK</given-names></string-name>. <article-title>Pilot study evaluating the use of <italic>Emblica officinalis</italic> standardized fruit extract in cardio-respiratory improvement and antioxidant status of volunteers with smoking history</article-title>. <source><italic toggle="yes">J Herb Med</italic></source>. <year>2014</year>;<volume>4</volume>(<issue>4</issue>):<fpage>188</fpage>&#x02013;<lpage>194</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.hermed.2014.09.002</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Khanna</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Das</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Spieldenner</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rink</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Roy</surname>
<given-names>S</given-names></string-name>. <article-title>Supplementation of a standardized extract from <italic>Phyllanthus emblica</italic> Improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults</article-title>. <source><italic toggle="yes">J Med Food</italic></source>. <year>2015</year>;<volume>18</volume>(<issue>4</issue>):<fpage>415</fpage>&#x02013;<lpage>420</lpage>. doi:<pub-id pub-id-type="doi">10.1089/jmf.2014.0178</pub-id><pub-id pub-id-type="pmid">25756303</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Fatima</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pingali</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Muralidhar</surname>
<given-names>N</given-names></string-name>. <article-title>Study of pharmacodynamic interaction of <italic>Phyllanthus emblica</italic> extract with clopidogrel and ecosprin in patients with type II diabetes mellitus</article-title>. <source><italic toggle="yes">Phytomedicine</italic></source>. <year>2014</year>;<volume>21</volume>(<issue>5</issue>):<fpage>579</fpage>&#x02013;<lpage>585</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phymed.2013.10.024</pub-id><pub-id pub-id-type="pmid">24291054</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Thirunavukkarasu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Selvaraju</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Tapias</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Sanchez</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Palesty</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Maulik</surname>
<given-names>N</given-names></string-name>. <article-title>Protective effects of Phyllanthus emblica against myocardial ischemia-reperfusion injury: the role of PI3-kinase/glycogen synthase kinase 3&#x003b2;/&#x003b2;-catenin pathway</article-title>. <source><italic toggle="yes">J Physiol Biochem</italic></source>. <year>2015</year>;<volume>71</volume>(<issue>4</issue>):<fpage>623</fpage>&#x02013;<lpage>626</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13105-015-0426-8</pub-id><pub-id pub-id-type="pmid">26342597</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Fatima</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pingali</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Pilli</surname>
<given-names>R</given-names></string-name>. <article-title>Evaluation of Phyllanthus emblica extract on cold pressor induced cardiovascular changes in healthy human subjects</article-title>. <source><italic toggle="yes">Pharmacognosy Res</italic></source>. <year>2014</year>;<volume>6</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.4103/0974-8490.122914</pub-id><pub-id pub-id-type="pmid">24497739</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Usharani</surname>
<given-names>P</given-names></string-name>, <string-name><surname>SudhaRani</surname>
<given-names>E</given-names></string-name>, <string-name><surname>KiranKishore</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Raveendranath</surname>
<given-names>P</given-names></string-name>. <article-title>Evaluation of the effect of a standardized aqueous extract of the fruits of Emblica officinalis on mental stress induced cardiovascular changes in healthy human subjects</article-title>. <source><italic toggle="yes">IJPSR</italic></source>. <year>2017</year>;<volume>8</volume>(<issue>10</issue>):<fpage>4138</fpage>&#x02013;<lpage>4146</lpage>.</mixed-citation></ref><ref id="CIT0034"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Biswas</surname>
<given-names>TK</given-names></string-name>, <string-name><surname>Pandit</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mondal</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia</article-title>. <source><italic toggle="yes">Andrologia</italic></source>. <year>2010</year>;<volume>42</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.1111/and.2009.42.issue-1</pub-id><pub-id pub-id-type="pmid">20078516</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Pandit</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Biswas</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jana</surname>
<given-names>U</given-names></string-name>, <string-name><surname>De</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Mukhopadhyay</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Biswas</surname>
<given-names>TK</given-names></string-name>. <article-title>Clinical evaluation of puri&#x0fb01;ed Shilajit on testosterone levels in healthy volunteers</article-title>. <source><italic toggle="yes">Andrologia</italic></source>. <year>2015</year>;<volume>xx</volume>:<fpage>1</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0036"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Das</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Datta</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Rhea</surname>
<given-names>B</given-names></string-name>, et al. <article-title>The human skeletal muscle transcriptome in response to oral shilajit supplementation</article-title>. <source><italic toggle="yes">J Med Food</italic></source>. <year>2016</year>;<volume>19</volume>(<issue>7</issue>):<fpage>701</fpage>&#x02013;<lpage>709</lpage>. doi:<pub-id pub-id-type="doi">10.1089/jmf.2016.0010</pub-id><pub-id pub-id-type="pmid">27414521</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Niranjan</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ramakanth</surname>
<given-names>GSH</given-names></string-name>, <string-name><surname>Fatima</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Usharani</surname>
<given-names>P</given-names></string-name>. <article-title>Evaluation of the effect of purified aqueous extract of shilajit in modifying cardiovascular risk with special reference to endothelial dysfunction in patients with type 2 diabetes mellitus</article-title>. <source><italic toggle="yes">Int J Ayur Pharma Res</italic></source>. <year>2016</year>;<volume>4</volume>(<issue>4</issue>):<fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0038"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Lawley</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gupta</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Goad</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Canerdy</surname>
<given-names>TD</given-names></string-name>, <string-name><surname>Kalidindi</surname>
<given-names>SR</given-names></string-name>. <article-title>Anti-inflammatory and antiarthritic efficacy and safety of purified shilajit in moderately arthritic dogs</article-title>. <source><italic toggle="yes">J Vet Sci Anim Husb</italic></source>. <year>2013</year>;<volume>1</volume>(<issue>3</issue>):<fpage>302</fpage>.</mixed-citation></ref><ref id="CIT0039"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Das</surname>
<given-names>A</given-names></string-name>, <string-name><surname>El Masry</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Gnyawali</surname>
<given-names>SC</given-names></string-name>, et al. <article-title>Skin transcriptome of middle-aged women supplemented with natural herbo-mineral shilajit shows induction of microvascular and extracellular matrix mechanisms</article-title>. <source><italic toggle="yes">J Am Coll Nutr</italic></source>. <year>2019</year>;<volume>38</volume>(<issue>6</issue>):<fpage>526</fpage>&#x02013;<lpage>536</lpage>. doi:<pub-id pub-id-type="doi">10.1080/07315724.2018.1564088</pub-id><pub-id pub-id-type="pmid">31161927</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Joukar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Najafipour</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Dabiri</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sheibani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sharokhi</surname>
<given-names>N</given-names></string-name>. <article-title>Cardioprotective effect of mumie (shilajit) on experimentally induced myocardial injury</article-title>. <source><italic toggle="yes">Cardiovasc Toxicol</italic></source>. <year>2014</year>;<volume>14</volume>(<issue>3</issue>):<fpage>214</fpage>&#x02013;<lpage>221</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12012-014-9245-3</pub-id><pub-id pub-id-type="pmid">24448712</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Biswas</surname>
<given-names>TK</given-names></string-name>, <string-name><surname>Polley</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Pandit</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Effects of adjunct therapy of a proprietary herbo-chromium supplement in type 2 diabetes: a randomized clinical trial</article-title>. <source><italic toggle="yes">Int J Diabetes Dev Ctries</italic></source>. <year>2010</year>;<volume>30</volume>(<issue>3</issue>):<fpage>153</fpage>&#x02013;<lpage>161</lpage>. doi:<pub-id pub-id-type="doi">10.4103/0973-3930.66512</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Peng</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>X</given-names></string-name>. <article-title>Controlling diabetes by chromium complexes: the role of the ligands</article-title>. <source><italic toggle="yes">J Inorg Biochem</italic></source>. <year>2015</year>;<volume>146</volume>:<fpage>97</fpage>&#x02013;<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jinorgbio.2015.01.002</pub-id><pub-id pub-id-type="pmid">25631328</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Saiyed</surname>
<given-names>ZM</given-names></string-name>, <string-name><surname>Lugo</surname>
<given-names>JP</given-names></string-name>. <article-title>Impact of chromium dinicocysteinate supplementation on inflammation, oxidative stress, and insulin resistance in type 2 diabetic subjects: an exploratory analysis of a randomized, double-blind, placebo-controlled study</article-title>. <source><italic toggle="yes">Food Nutr Res</italic></source>. <year>2016</year>;<volume>60</volume>:<fpage>31762</fpage>. doi:<pub-id pub-id-type="doi">10.3402/fnr.v60.31762</pub-id><pub-id pub-id-type="pmid">27687012</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Chowienczyk</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Kelly</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>MacCallum</surname>
<given-names>H</given-names></string-name>, et al. <article-title>Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus</article-title>. <source><italic toggle="yes">J Am Coll Cardiol</italic></source>. <year>1999</year>;<volume>34</volume>(<issue>7</issue>):<fpage>2007</fpage>&#x02013;<lpage>2014</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0735-1097(99)00441-6</pub-id><pub-id pub-id-type="pmid">10588217</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Naidu</surname>
<given-names>MUR</given-names></string-name>, <string-name><surname>Sridhar</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Usharani</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mateen</surname>
<given-names>AA</given-names></string-name>. <article-title>Comparison of two &#x003b2;2 adrenoceptor agonists by different routes of administration to assess human endothelial function</article-title>. <source><italic toggle="yes">Indian J Pharmacol</italic></source>. <year>2007</year>;<volume>39</volume>(<issue>3</issue>):<fpage>168</fpage>&#x02013;<lpage>169</lpage>. doi:<pub-id pub-id-type="doi">10.4103/0253-7613.33439</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Millasseau</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Kelly</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Ritter</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Chowienczyk</surname>
<given-names>PJ</given-names></string-name>. <article-title>Determination of age-related increases in large artery stiffness by digital pulse contour analysis</article-title>. <source><italic toggle="yes">Clin Sci</italic></source>. <year>2002</year>;<volume>103</volume>:<fpage>371</fpage>&#x02013;<lpage>377</lpage>. doi:<pub-id pub-id-type="doi">10.1042/cs1030371</pub-id><pub-id pub-id-type="pmid">12241535</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Miranda</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Espey</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Wink</surname>
<given-names>DA</given-names></string-name>. <article-title>A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite</article-title>. <source><italic toggle="yes">Nitric Oxide</italic></source>. <year>2001</year>;<volume>5</volume>(<issue>1</issue>):<fpage>62</fpage>&#x02013;<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1006/niox.2000.0319</pub-id><pub-id pub-id-type="pmid">11178938</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Vidyasagar</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Karunakar</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Reddy</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Rajnarayana</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Surender</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Krishna</surname>
<given-names>DR</given-names></string-name>. <article-title>Oxidative stress and antioxidant status in acute organophosphorous insecticide poisoning</article-title>. <source><italic toggle="yes">Indian J Pharmacol</italic></source>. <year>2004</year>;<volume>36</volume>(<issue>2</issue>):<fpage>76</fpage>&#x02013;<lpage>79</lpage>.</mixed-citation></ref><ref id="CIT0049"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Ellman</surname>
<given-names>GL</given-names></string-name>. <article-title>Tissue sulfhydryl groups</article-title>. <source><italic toggle="yes">Arch Biochem Biophys</italic></source>. <year>1959</year>;<volume>82</volume>(<issue>1</issue>):<fpage>70</fpage>&#x02013;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0003-9861(59)90090-6</pub-id><pub-id pub-id-type="pmid">13650640</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Wong</surname>
<given-names>CY</given-names></string-name>, <string-name><surname>Yiu</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>SW</given-names></string-name>, et al. <article-title>Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in subjects with Type 2 diabetes mellitus</article-title>. <source><italic toggle="yes">Diabet Med</italic></source>. <year>2010</year>;<volume>27</volume>(<issue>1</issue>):<fpage>54</fpage>&#x02013;<lpage>60</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1464-5491.2009.02869.x</pub-id><pub-id pub-id-type="pmid">20121889</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Siniarski</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Haberka</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mostowik</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: a randomized, double-blind, placebo-controlled study (Omega FMD)</article-title>. <source><italic toggle="yes">Atherosclerosis</italic></source>. <year>2018</year>;<volume>271</volume>:<fpage>148</fpage>&#x02013;<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.02.030</pub-id><pub-id pub-id-type="pmid">29518747</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Usharani</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Devi</surname>
<given-names>CG</given-names></string-name>, <string-name><surname>Kishore</surname>
<given-names>KK</given-names></string-name>, <string-name><surname>Kumar</surname>
<given-names>CU</given-names></string-name>. <article-title>Effect of proprietary chromium complex and its individual components versus chromium picolinate, chromium polynicotinate and chromium dinicocysteinate on endothelial function, biomarkers and lipid profile in type 2 diabetics - a randomized, double-blind, placebo-controlled study</article-title>. <source><italic toggle="yes">Int J Pharm Sci Res</italic></source>. <year>2017</year>;<volume>8</volume>(<issue>5</issue>):<fpage>2267</fpage>&#x02013;<lpage>2276</lpage>.</mixed-citation></ref><ref id="CIT0053"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Kerksick</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Willoughby</surname>
<given-names>D</given-names></string-name>. <article-title>The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress</article-title>. <source><italic toggle="yes">J Int Soc Sports Nutr</italic></source>. <year>2005</year>;<volume>2</volume>:<fpage>38</fpage>&#x02013;<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1186/1550-2783-2-2-38</pub-id><pub-id pub-id-type="pmid">18500954</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Shidfar</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Keshavarz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hosseyni</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ameri</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yarahmadi</surname>
<given-names>S</given-names></string-name>. <article-title>Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes subjects</article-title>. <source><italic toggle="yes">East Mediterr Health J</italic></source>. <year>2008</year>;<volume>14</volume>(<issue>2</issue>):<fpage>305</fpage>&#x02013;<lpage>313</lpage>.<pub-id pub-id-type="pmid">18561722</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Sorto-Gomez</surname>
<given-names>TE</given-names></string-name>, <string-name><surname>Ortiz</surname>
<given-names>GG</given-names></string-name>, <string-name><surname>Pacheco-Moises</surname>
<given-names>FP</given-names></string-name>, et al. <article-title>Effect of fish oil on glutathione redox system in multiple sclerosis</article-title>. <source><italic toggle="yes">Am J Neurodegener Dis</italic></source>. <year>2016</year>;<volume>5</volume>(<issue>2</issue>):<fpage>145</fpage>&#x02013;<lpage>151</lpage>.<pub-id pub-id-type="pmid">27335704</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Jin</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Loscalzo</surname>
<given-names>J</given-names></string-name>. <article-title>Vascular nitric oxide: formation and function</article-title>. <source><italic toggle="yes">J Blood Med</italic></source>. <year>2010</year>;<volume>1</volume>:<fpage>147</fpage>&#x02013;<lpage>162</lpage>.</mixed-citation></ref><ref id="CIT0057"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Asemi</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Soleimani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shakeri</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Mazroii</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Esmaillzadeh</surname>
<given-names>A</given-names></string-name>. <article-title>Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis subjects</article-title>. <source><italic toggle="yes">Int Urol Nephrol</italic></source>. <year>2016</year>;<volume>48</volume>(<issue>11</issue>):<fpage>1887</fpage>&#x02013;<lpage>1895</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11255-016-1399-4</pub-id><pub-id pub-id-type="pmid">27554670</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Yamada</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Yoshida</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nakano</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid</article-title>. <source><italic toggle="yes">Arterioscler Thromb Vasc Biol</italic></source>. <year>2008</year>;<volume>28</volume>(<issue>12</issue>):<fpage>2173</fpage>&#x02013;<lpage>2179</lpage>. doi:<pub-id pub-id-type="doi">10.1161/ATVBAHA.108.171736</pub-id><pub-id pub-id-type="pmid">18948636</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Hocaoglu-Emre</surname>
<given-names>FS</given-names></string-name>, <string-name><surname>Saribal</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Yenmis</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Guvenen</surname>
<given-names>G</given-names></string-name>. <article-title>Vascular cell adhesion molecule 1, intercellular adhesion molecule 1, and cluster of differentiation 146 levels in patients with Type 2 diabetes with complications</article-title>. <source><italic toggle="yes">Endocrinol Metab (Seoul)</italic></source>. <year>2017</year>;<volume>32</volume>(<issue>1</issue>):<fpage>99</fpage>&#x02013;<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.3803/EnM.2017.32.1.99</pub-id><pub-id pub-id-type="pmid">28345319</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Calder</surname>
<given-names>PC</given-names></string-name>. <article-title>Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?</article-title>
<source><italic toggle="yes">Br J Clin Pharmacol</italic></source>. <year>2013</year>;<volume>75</volume>(<issue>3</issue>):<fpage>645</fpage>&#x02013;<lpage>662</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04374.x</pub-id><pub-id pub-id-type="pmid">22765297</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Kamath</surname>
<given-names>DY</given-names></string-name>, <string-name><surname>Xavier</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Sigamani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pais</surname>
<given-names>P</given-names></string-name>. <article-title>High sensitivity C-reactive protein (hsCRP) &#x00026; cardiovascular disease: an Indian perspective</article-title>. <source><italic toggle="yes">Indian J Med Res</italic></source>. <year>2015</year>;<volume>142</volume>(<issue>3</issue>):<fpage>261</fpage>&#x02013;<lpage>268</lpage>. doi:<pub-id pub-id-type="doi">10.4103/0971-5916.166582</pub-id><pub-id pub-id-type="pmid">26458341</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Schiano</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Laurenzano</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Brevetti</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function</article-title>. <source><italic toggle="yes">Clin Nutr</italic></source>. <year>2008</year>;<volume>27</volume>(<issue>2</issue>):<fpage>241</fpage>&#x02013;<lpage>247</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clnu.2007.11.007</pub-id><pub-id pub-id-type="pmid">18237823</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Mackay</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Ford</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Thies</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Fielding</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bachoo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Brittenden</surname>
<given-names>J</given-names></string-name>. <article-title>Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in subjects with peripheral arterial disease</article-title>. <source><italic toggle="yes">Atherosclerosis</italic></source>. <year>2012</year>;<volume>221</volume>(<issue>2</issue>):<fpage>514</fpage>&#x02013;<lpage>520</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.12.041</pub-id><pub-id pub-id-type="pmid">22296885</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Usharani</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kishan</surname>
<given-names>PV</given-names></string-name>, <string-name><surname>Fatima</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Kumar</surname>
<given-names>UC</given-names></string-name>. <article-title>A comparative study to evaluate the effect of highly standardised aqueous extracts of <italic>Phyllanthus emblica</italic>, withania somnifera and their combination on endothelial dysfunction and biomarkers in subjects with type II diabetes mellitus</article-title>. <source><italic toggle="yes">IJPSR</italic></source>. <year>2014</year>;<volume>5</volume>(<issue>7</issue>):<fpage>2687</fpage>&#x02013;<lpage>2697</lpage>.</mixed-citation></ref><ref id="CIT0065"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Harris</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Ginsberg</surname>
<given-names>HN</given-names></string-name>, <string-name><surname>Arunakul</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Safety and efficacy of Omacor in severe hypertriglyceridemia</article-title>. <source><italic toggle="yes">J Cardiovasc Risk</italic></source>. <year>1997</year>;<volume>4</volume>(<issue>5&#x02013;6</issue>):<fpage>385</fpage>&#x02013;<lpage>391</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00043798-199710000-00011</pub-id><pub-id pub-id-type="pmid">9865671</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Koski</surname>
<given-names>RR</given-names></string-name>. <article-title>Omega-3-acid Ethyl Esters (Lovaza) For severe hypertriglyceridemia</article-title>. <source><italic toggle="yes">Pharm Ther</italic></source>. <year>2008</year>;<volume>33</volume>(<issue>5</issue>):<fpage>271</fpage>&#x02013;<lpage>303</lpage>.</mixed-citation></ref><ref id="CIT0067"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Bays</surname>
<given-names>HE</given-names></string-name>, <string-name><surname>Ballantyne</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Kastelein</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Isaacsohn</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Braeckman</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Soni</surname>
<given-names>PN</given-names></string-name>. <article-title>Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)</article-title>. <source><italic toggle="yes">Am J Cardiol</italic></source>. <year>2011</year>;<volume>108</volume>(<issue>5</issue>):<fpage>682</fpage>&#x02013;<lpage>690</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjcard.2011.04.015</pub-id><pub-id pub-id-type="pmid">21683321</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Kataoka</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Uno</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Puri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Nicholls</surname>
<given-names>SJ</given-names></string-name>. <article-title>Epanova(<sup>&#x000ae;</sup>) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy</article-title>. <source><italic toggle="yes">Future Cardiol</italic></source>. <year>2013</year>;<volume>9</volume>(<issue>2</issue>):<fpage>177</fpage>&#x02013;<lpage>186</lpage>. doi:<pub-id pub-id-type="doi">10.2217/fca.13.4</pub-id><pub-id pub-id-type="pmid">23463969</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Cicero</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Rosticci</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Morbini</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial</article-title>. <source><italic toggle="yes">Arch Med Sci</italic></source>. <year>2016</year>;<volume>12</volume>(<issue>3</issue>):<fpage>507</fpage>&#x02013;<lpage>512</lpage>. doi:<pub-id pub-id-type="doi">10.5114/aoms.2016.59923</pub-id><pub-id pub-id-type="pmid">27279841</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Sawada</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Tsubata</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hashimoto</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly - diagnosed impaired glucose metabolism subjects with coronary artery disease. An open label, single blinded, prospective randomized controlled trial</article-title>. <source><italic toggle="yes">Cardiovasc Diabetol</italic></source>. <year>2016</year>;<volume>15</volume>(<issue>1</issue>):<fpage>121</fpage>.<pub-id pub-id-type="pmid">27565734</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Brown</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Brainard</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2019</year>;<volume>366</volume>:<fpage>l4697</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.l4697</pub-id><pub-id pub-id-type="pmid">31434641</pub-id></mixed-citation></ref></ref-list></back></article>